HK1108825A1 - Compositions and methods for treating leukemia - Google Patents
Compositions and methods for treating leukemiaInfo
- Publication number
- HK1108825A1 HK1108825A1 HK07112180.8A HK07112180A HK1108825A1 HK 1108825 A1 HK1108825 A1 HK 1108825A1 HK 07112180 A HK07112180 A HK 07112180A HK 1108825 A1 HK1108825 A1 HK 1108825A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- compositions
- treating leukemia
- mammal
- leukemia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65148204P | 2004-08-10 | 2004-08-10 | |
PCT/US2005/028233 WO2006020618A1 (en) | 2004-08-10 | 2005-08-09 | Compositions and methods for treating leukemia |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1108825A1 true HK1108825A1 (en) | 2008-05-23 |
Family
ID=35414880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07112180.8A HK1108825A1 (en) | 2004-08-10 | 2007-11-08 | Compositions and methods for treating leukemia |
Country Status (12)
Country | Link |
---|---|
US (2) | US20090028933A1 (da) |
EP (1) | EP1781255B1 (da) |
JP (1) | JP5199666B2 (da) |
AT (1) | ATE545408T1 (da) |
AU (1) | AU2005272946B2 (da) |
CA (1) | CA2576222C (da) |
CY (1) | CY1112736T1 (da) |
DK (1) | DK1781255T3 (da) |
ES (1) | ES2382337T3 (da) |
HK (1) | HK1108825A1 (da) |
PT (1) | PT1781255E (da) |
WO (1) | WO2006020618A1 (da) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6723338B1 (en) * | 1999-04-01 | 2004-04-20 | Inex Pharmaceuticals Corporation | Compositions and methods for treating lymphoma |
WO2011041914A1 (en) * | 2009-10-09 | 2011-04-14 | University Health Network (Uhn) | Use of flubendazole and vinca alkaloids for treatment of hematological diseases |
CA2818018C (en) * | 2010-12-08 | 2016-02-02 | F. Hoffmann-La Roche Ag | Liposomal formulation of dalcetrapib |
MX2015005992A (es) | 2012-11-20 | 2016-03-07 | Spectrum Pharmaceuticals Inc | Metodo mejorado para la preparacion de la vincristina liposomal encapsulada para el uso terapeutico. |
US9757385B2 (en) | 2013-11-27 | 2017-09-12 | Merck Sharp & Dohme Corp. | Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds |
AU2015252844A1 (en) * | 2014-05-02 | 2016-11-03 | Kay NOEL | Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds |
JP2018506533A (ja) * | 2015-02-12 | 2018-03-08 | シアトル ジェネティックス, インコーポレイテッド | Cd19−adc及びビンクリスチンを使用する組み合わせ療法 |
JP6793401B2 (ja) * | 2015-03-11 | 2020-12-02 | 国立研究開発法人理化学研究所 | 難治性白血病治療薬 |
TWI678213B (zh) | 2015-07-22 | 2019-12-01 | 美商史倍壯製藥公司 | 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物 |
CN111658636B (zh) * | 2020-06-12 | 2021-04-13 | 桂林医学院 | 穿心莲内酯与地塞米松联用在制备复方抗急性淋巴细胞白血病药物中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4906476A (en) * | 1988-12-14 | 1990-03-06 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs in lungs |
CA2366787C (en) * | 1999-04-01 | 2013-03-12 | Inex Pharmaceuticals Corp. | Compositions and methods for treating lymphoma |
US7311924B2 (en) * | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
US6723338B1 (en) * | 1999-04-01 | 2004-04-20 | Inex Pharmaceuticals Corporation | Compositions and methods for treating lymphoma |
-
2005
- 2005-08-09 WO PCT/US2005/028233 patent/WO2006020618A1/en active Application Filing
- 2005-08-09 CA CA2576222A patent/CA2576222C/en not_active Expired - Fee Related
- 2005-08-09 EP EP05783719A patent/EP1781255B1/en not_active Not-in-force
- 2005-08-09 ES ES05783719T patent/ES2382337T3/es active Active
- 2005-08-09 AU AU2005272946A patent/AU2005272946B2/en not_active Ceased
- 2005-08-09 DK DK05783719.7T patent/DK1781255T3/da active
- 2005-08-09 JP JP2007525727A patent/JP5199666B2/ja not_active Expired - Fee Related
- 2005-08-09 PT PT05783719T patent/PT1781255E/pt unknown
- 2005-08-09 AT AT05783719T patent/ATE545408T1/de active
-
2007
- 2007-11-08 HK HK07112180.8A patent/HK1108825A1/xx not_active IP Right Cessation
-
2008
- 2008-02-11 US US12/069,488 patent/US20090028933A1/en not_active Abandoned
-
2011
- 2011-07-06 US US13/177,367 patent/US20120164211A1/en not_active Abandoned
-
2012
- 2012-05-14 CY CY20121100449T patent/CY1112736T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ATE545408T1 (de) | 2012-03-15 |
ES2382337T3 (es) | 2012-06-07 |
EP1781255A1 (en) | 2007-05-09 |
WO2006020618A1 (en) | 2006-02-23 |
EP1781255B1 (en) | 2012-02-15 |
JP5199666B2 (ja) | 2013-05-15 |
JP2008509911A (ja) | 2008-04-03 |
AU2005272946B2 (en) | 2012-01-12 |
US20120164211A1 (en) | 2012-06-28 |
CY1112736T1 (el) | 2016-02-10 |
WO2006020618A8 (en) | 2006-11-02 |
US20090028933A1 (en) | 2009-01-29 |
AU2005272946A1 (en) | 2006-02-23 |
DK1781255T3 (da) | 2012-05-29 |
CA2576222A1 (en) | 2006-02-23 |
PT1781255E (pt) | 2012-05-21 |
CA2576222C (en) | 2014-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1108825A1 (en) | Compositions and methods for treating leukemia | |
RS20070029A (en) | Compositions for delivering highly water soluble drugs | |
FR13C0062I1 (da) | ||
WO2005110477A3 (en) | Combination therapies for cancer and proliferative angiopathies | |
IL175714A0 (en) | Quinazolinone compounds as anticancer agents | |
TW200718689A (en) | 2-Amino-quinazolin-5-ones | |
PL1742644T3 (pl) | Kompozycja terapeutyczna zawierająca co najmniej jedną pochodną pirolobenzodiazepiny i fludarabiny | |
WO2004087075A3 (en) | Compositions and methods for treating cancer | |
SG160412A1 (en) | Anti-igfr1 antibody therapeutic combinations | |
WO2005070930A3 (en) | Tetrahydrocarboline compounds as anticancer agents | |
TW200621240A (en) | Cancer treatments | |
WO2005094376A3 (en) | Synergistic methods and compositions for treating cancer | |
WO2004030627A3 (en) | Synergistic methods and compositions for treating cancer | |
SG155880A1 (en) | Multiparticulates of preferably an opioid, and method of manufacturing using extrusion | |
JO2464B1 (en) | Formulas contain actinacidine and binary sugars | |
SG164368A1 (en) | Treatment of cancer | |
WO2004006859A3 (en) | Platinum compound | |
SI1781296T1 (sl) | Kinazolinski derivati in njihova uporaba pri zdravljenju trombocitemije | |
IL190632A0 (en) | Biphenyl derivatives and pharmaceutical compositions containing the same | |
WO2007008200A8 (en) | Wortmannin analogs and methods of using same in combination with chemotherapeutic agents | |
MX2007002525A (es) | Compuestos de difeniletileno y usos de los mismos. | |
IL190774A0 (en) | Pharmaceutical compositions containing a jorumycin-renieramycin-or saframycin-related compounds for treating proliferative diseases | |
MXPA05011213A (es) | Combinacion de un inhibidor de ciclooxigenasa-2 y un agente antineoplasico tipo alquilacion para tratamiento de neoplasia. | |
WO2006002088A3 (en) | Amino-quinazoline derivatives as antitumor agents | |
WO2005053725A3 (en) | Cancer treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20220809 |